Lv7
3490 积分 2024-07-05 加入
Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial
14天前
已完结
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
15天前
已完结
The role of endothelin receptor antagonists in IgA nephropathy
17天前
已完结
Endothelin receptor antagonists in chronic kidney disease
17天前
已完结
Atrasentan in Patients with IgA Nephropathy
17天前
已完结
Effects of Therapies on Proteinuria and Estimated Glomerular Filtration Rate in IgA Nephropathy: Meta-Analysis of Randomized Trials
17天前
已完结
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
23天前
已完结
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
23天前
已完结
Long-term outcomes of IgA nephropathy in China
23天前
已完结
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
24天前
已完结
皖公网安备34019202002308
